QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin's automated LIAISON® XS platform. The approval widens the accessibility of U.S. customers to automation solutions for processing QIAGEN's leading blood-based test for latent tuberculosis (TB) detection and support the conversion from the traditional tuberculin skin tests that were developed over a century ago. The highly automated workflow on LIAISON® platforms gives QuantiFERON® customers a powerful, flexible automated option for all throughput ranges.

The addition of the fully automated LIAISON® XS platform to the already approved use of this assay on the LIAISON®XL version expands the range of potential customers to include experts at smaller healthcare clinics alongside those at larger hospitals and medical centers and reference laboratories. LIAISON® QuantiFERON®-TB Gold Plus is an interferon-gamma release assay (IGRA) developed by QIAGEN and DiaSorin to offer streamlined laboratory automation for latent TB screening. QuantiFERON-TB – which tests for interferon-gamma released from T-cells that have encountered TB bacteria – has been available on LIAISON® XL platforms in the U.S. since 2019.

QIAGEN and DiaSorin will continue to cooperate closely on the promotion and sale of their joint solutions for TB testing to make sure their customers reap the full benefit of their collaboration. TB is one of the biggest global healthcare problems. About one third of the world's population is estimated by the World Health Organization (WHO) to carry the infection in its latent form – about 2.5 billion people. Left untreated, up to 10% of them will become active TB sufferers.

The disease is one of world's top 10 causes of death, claiming around 1.7 million victims each year. The highly contagious bacterial infection is spread primarily through coughing by patients with the active, lung-based form of the disease. But the bacterium can also cause infection without disease symptoms, a condition known as latent tuberculosis (LTBI).

As part of programs to eradicate TB, the WHO and other international organizations have expanded guidelines for screening high-risk individuals and treating those with LTBI to help prevent further contagion.